e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Novel drugs and biomarkers in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Involvement of the JAK-STAT3 pathway in a lipopolysaccharide-induced rat model of airway inflammation
E. Calama, A. Domenech, C. Carreño, J. De Alba, N. Prats, M. Miralpeix, I. Ramis (Sant Feliu de LLobregat, Spain)
Source:
Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Session:
Novel drugs and biomarkers in respiratory medicine
Session type:
Thematic Poster Session
Number:
733
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Calama, A. Domenech, C. Carreño, J. De Alba, N. Prats, M. Miralpeix, I. Ramis (Sant Feliu de LLobregat, Spain). Involvement of the JAK-STAT3 pathway in a lipopolysaccharide-induced rat model of airway inflammation. Eur Respir J 2013; 42: Suppl. 57, 733
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Comparison of pulmonary versus extrapulmonary models of induced acute lung injury in rat
Source: Annual Congress 2013 –Experimental models in critical care
Year: 2013
Novel experimental model of maintained acute lung injury
Source: Annual Congress 2013 –Experimental models in critical care
Year: 2013
Characterization of an acute influenza infection in a murine model of allergic asthma and responses to corticosteroid
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
Targeting PI3KΔ or JAK in T-cells from COPD and severe asthma subjects reduces corticosteroid insensitive inflammatory responses
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Assessment of ATP degradation in bronchoalveolar lavage fluid
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
Bronchoalveolar lavage tryptase levels are correlated with type 2 airway inflammation in mild asthma
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
The use of bronchoalveolar lavage (BAL) to assess lower airways inflammation in asthma
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
Determinants of oxidants load in broncho-alveiolar milieu
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
The effect of lipopolysaccharide-contaminated ovalbumin on airway inflammation and remodeling in a chronic murine asthma model
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
Galectin-9 attenuates elastase-induced emphysema by reducing neutrophil chemotaxis in mice
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Investigation of mitochondria homeostasis and mitophagy in bronchoalveolar lavage fluid (BALF) cells in pulmonary fibrosis
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
Studies on hepatocyte growth factor (HGF) in bronchoalveolar lavage (BAL) do not support the concept on its antifibrotic properties in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Acid sphingomyelinase deficiency improves lung function in allergen-induced asthma in mice
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Bronchoalveolar lavage neuregulin-1 is elevated in acute lung injury and correlates with inflammation
Source: Eur Respir J 2013; 41: 396-401
Year: 2013
Activation of MMP-9 in BAL is increased in COPD exacerbation independently of smoking, lung function, microbiology and treatment
Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases
Year: 2014
Acid sphingomyelinase mediates IL-6 release in experimental LPS-induced lung injury
Source: International Congress 2014 – Experimental models in acute lung injury
Year: 2014
Effect of mast cells degranulation blockade on the inflammatory response outcome in the COPD model
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Pathogenetic pathways in pulmonary fibrosis: The role of bronchoalveolar lavage (BAL) cellularity in relation to epithelial injury
Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Year: 2010
Effects of cyclosporin H on airway inflammatory responses induced by mitochondrial damage-associated molecular patterns
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Expression of matrix metalloproteinases in bronchoalveolar cells in COPD and in COPD phenotypes
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept